After Novo Nordisk (NVO) announced an EBIT guide cut on restructuring costs, with the EBIT growth guidance range lowered from 10%-16% to 4%-10%, BofA noted that this was the company’s third profit warning and argues that another one is “still possible” given the current “disappointing” total prescriptions trajectory. BofA has a Neutral rating and price target of DKK 375 on Novo Nordisk shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk lowers operating profit growth outlook for 2025 to 4%-10%
- Novo Nordisk’s Strategic Restructuring Faces Uncertainty Amid Competitive Pressures
- Novo Nordisk Announces Major Transformation to Boost Growth in Diabetes and Obesity
- Novo Nordisk to reduce workforce by 9,000 positions
- Novo Nordisk Stock (NVO) Under Pressure as It Cuts Jobs and Lowers Outlook